Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

NCT ID: NCT02291679

Last Updated: 2017-06-15

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1223 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this trial was to determine the efficacy and safety of linaclotide 72 ug administered once daily to patients with chronic idiopathic constipation (CIC). The primary efficacy parameter is the percentage of participants in each dosing group that meet the protocol definition for complete spontaneous bowel movement (CSBM) Overall Responder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial also included a 145 ug linaclotide treatment arm (an FDA-approved dose for CIC) as an established positive control to validate the study design.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Idiopathic Constipation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

72 μg linaclotide

72 μg oral linaclotide, once daily for 12 weeks

Group Type EXPERIMENTAL

Linaclotide

Intervention Type DRUG

145 μg linaclotide

145 μg oral linaclotide, once daily for 12 weeks

Group Type EXPERIMENTAL

Linaclotide

Intervention Type DRUG

Placebo

matching placebo, once daily for 12 weeks

Group Type PLACEBO_COMPARATOR

Matching Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Linaclotide

Intervention Type DRUG

Matching Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Linzess Constella

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has completed a colonoscopy if one is needed according to the American Gastroenterological Association (AGA) criteria, with no clinically significant findings
* Patient has no clinically significant findings on a physical examination and clinical laboratory tests
* Patient meets protocol criteria for CIC: reports \< 3 bowel movements (BMs) per week and reports one or more of the following during ≥ 25% of BMs: straining, lumpy or hard stools, sensation of incomplete evacuation during the 3 months before the diagnosis with the onset at least 6 months before the diagnosis
* Patient is compliant with daily interactive voice response system (IVRS) calls
* Patient reports an average of \< 3 complete spontaneous BMs (CSBMs) and ≤ 6 SBMs per week by the IVRS over the 14 calendar days before the Randomization Visit and the calendar day of Randomization.

Exclusion Criteria

* Patient has history of loose or watery stools
* Patient has symptoms of or been diagnosed with irritable bowel syndrome (IBS)
* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility
* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments
* Patient has Bristol Stool Form Scale score of 7 during Pretreatment period.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Forest Laboratories

INDUSTRY

Sponsor Role collaborator

Ironwood Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bernard J Lavins, MD

Role: STUDY_CHAIR

Ironwood Pharmaceuticals, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ironwood Investigational Site

Huntsville, Alabama, United States

Site Status

Ironwood Investigational Site

Phoenix, Arizona, United States

Site Status

Ironwood Investigational Site

Tucson, Arizona, United States

Site Status

Ironwood Investigational Site

North Little Rock, Arkansas, United States

Site Status

Ironwood Investigational Site

Anaheim, California, United States

Site Status

Ironwood Investigational Site

Chula Vista, California, United States

Site Status

Ironwood Investigational Site

Garden Grove, California, United States

Site Status

Ironwood Investigational Site

La Mesa, California, United States

Site Status

Ironwood Investigational Site

North Hollywood, California, United States

Site Status

Ironwood Investigational Site

Orange, California, United States

Site Status

Ironwood Investigational Site

San Diego, California, United States

Site Status

Ironwood Investigational Site

Thousand Oaks, California, United States

Site Status

Ironwood Investigational Site

Colorado Springs, Colorado, United States

Site Status

Ironwood Investigational Site

Bristol, Connecticut, United States

Site Status

Ironwood Investigational Site

Boynton Beach, Florida, United States

Site Status

Ironwood Investigational Site

Coral Gables, Florida, United States

Site Status

Ironwood Investigational Site

DeLand, Florida, United States

Site Status

Ironwood Investigational Site

Hialeah, Florida, United States

Site Status

Ironwood Investigational Site

Inverness, Florida, United States

Site Status

Ironwood Investigational Site

Jupiter, Florida, United States

Site Status

Ironwood Investigational Site

Kissimmee, Florida, United States

Site Status

Ironwood Investigational Site

Lauderdale Lakes, Florida, United States

Site Status

Ironwood Investigational Site

Miami, Florida, United States

Site Status

Ironwood Investigational Site

Miami, Florida, United States

Site Status

Ironwood Investigational Site

Miami, Florida, United States

Site Status

Ironwood Investigational Site

Miami, Florida, United States

Site Status

Ironwood Investigational Site

Miami, Florida, United States

Site Status

Ironwood Investigational Site

Miami, Florida, United States

Site Status

Ironwood Investigational Site

Orlando, Florida, United States

Site Status

Ironwood Investigational Site

Ormond Beach, Florida, United States

Site Status

Ironwood Investigational Site

Port Orange County, Florida, United States

Site Status

Ironwood Investigational Site

South Miami, Florida, United States

Site Status

Ironwood Investigational Site

Tampa, Florida, United States

Site Status

Ironwood Investigational Site

West Palm Beach, Florida, United States

Site Status

Ironwood Investigational Site

Winter Park, Florida, United States

Site Status

Ironwood Investigational Site

Atlanta, Georgia, United States

Site Status

Ironwood Investigational Site

Oakwood, Georgia, United States

Site Status

Ironwood Investigational Site

Sandy Springs, Georgia, United States

Site Status

Ironwood Investigational Site

Evansville, Indiana, United States

Site Status

Ironwood Investigational Site

Bastrop, Louisiana, United States

Site Status

Ironwood Investigational Site

Metairie, Louisiana, United States

Site Status

Ironwood Investigational Site

Shreveport, Louisiana, United States

Site Status

Ironwood Investigational Site

Baltimore, Maryland, United States

Site Status

Ironwood Investigational Site

Chevy Chase, Maryland, United States

Site Status

Ironwood Investigational Site

Hagerstown, Maryland, United States

Site Status

Ironwood Investigational Site

Hollywood, Maryland, United States

Site Status

Ironwood Investigational Site

Boston, Massachusetts, United States

Site Status

Ironwood Investigational Site

Wellesley, Massachusetts, United States

Site Status

Ironwood Investigational Site

Chesterfield, Michigan, United States

Site Status

Ironwood Investigational Site

Troy, Michigan, United States

Site Status

Ironwood Investigational Site

Wyoming, Michigan, United States

Site Status

Ironwood Investigational Site

Jackson, Mississippi, United States

Site Status

Ironwood Investigational Site

St Louis, Missouri, United States

Site Status

Ironwood Investigational Site

Bozeman, Montana, United States

Site Status

Ironwood Investigational Site

Las Vegas, Nevada, United States

Site Status

Ironwood Investigational Site

Las Vegas, Nevada, United States

Site Status

Ironwood Investigational Site

Brooklyn, New York, United States

Site Status

Ironwood Investigational Site

Endwell, New York, United States

Site Status

Ironwood Investigational Site

Great Neck, New York, United States

Site Status

Ironwood Investigational Site

Charlotte, North Carolina, United States

Site Status

Ironwood Investigational Site

Charlotte, North Carolina, United States

Site Status

Ironwood Investigational Site

Greensboro, North Carolina, United States

Site Status

Ironwood Investigational Site

High Point, North Carolina, United States

Site Status

Ironwood Investigational Site

Lenoir, North Carolina, United States

Site Status

Ironwood Investigational Site

Raleigh, North Carolina, United States

Site Status

Ironwood Investigational Site

Wilmington, North Carolina, United States

Site Status

Ironwood Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Ironwood Investigational Site

Fargo, North Dakota, United States

Site Status

Ironwood Investigational Site

Cincinnati, Ohio, United States

Site Status

Ironwood Investigational Site

Cincinnati, Ohio, United States

Site Status

Ironwood Investigational Site

Columbus, Ohio, United States

Site Status

Ironwood Investigational Site

Mentor, Ohio, United States

Site Status

Ironwood Investigational Site

Sylvania, Ohio, United States

Site Status

Ironwood Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

Ironwood Investigational Site

Levittown, Pennsylvania, United States

Site Status

Ironwood Investigational Site

Anderson, South Carolina, United States

Site Status

Ironwood Investigational Site

Greer, South Carolina, United States

Site Status

Ironwood Investigational Site

Simpsonville, South Carolina, United States

Site Status

Ironwood Investigational Site

Dakota Dunes, South Dakota, United States

Site Status

Ironwood Investigational Site

Bristol, Tennessee, United States

Site Status

Ironwood Investigational Site

Chattanooga, Tennessee, United States

Site Status

Ironwood Investigational Site

Knoxville, Tennessee, United States

Site Status

Ironwood Investigational Site

Beaumont, Texas, United States

Site Status

Ironwood Investigational Site

Dallas, Texas, United States

Site Status

Ironwood Investigational Site

El Paso, Texas, United States

Site Status

Ironwood Investigational Site

Houston, Texas, United States

Site Status

Ironwood Investigational Site

Houston, Texas, United States

Site Status

Ironwood Investigational Site

Longview, Texas, United States

Site Status

Ironwood Investigational Site

San Antonio, Texas, United States

Site Status

Ironwood Investigational Site

San Antonio, Texas, United States

Site Status

Ironwood Investigational Site

San Antonio, Texas, United States

Site Status

Ironwood Investigational Site

South Ogden, Utah, United States

Site Status

Ironwood Investigational Site

Christiansburg, Virginia, United States

Site Status

Ironwood Investigational Site

Lynchburg, Virginia, United States

Site Status

Ironwood Investigational Site

La Crosse, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MCP-103-309

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect to Linaclotide on Colonic Motility
NCT06989268 COMPLETED PHASE4
Linaclotide for Colonoscopy Bowel Prep
NCT06692673 RECRUITING PHASE1/PHASE2